PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35081714-0	2022	Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.	pyrimidine	30-40	ret proto-oncogene	Homo sapiens	63-66	
35081714-0	2022	Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.	pyrimidine	30-40	ret proto-oncogene	Homo sapiens	71-74	
35081714-7	2022	Collectively, N-trisubstituted pyrimidine derivatives could serve as scaffolds for the discovery and development of potent inhibitors of type I RET and its gatekeeper mutant for the treatment of RET-driven cancers.	pyrimidine	31-41	ret proto-oncogene	Homo sapiens	144-147	
35081714-7	2022	Collectively, N-trisubstituted pyrimidine derivatives could serve as scaffolds for the discovery and development of potent inhibitors of type I RET and its gatekeeper mutant for the treatment of RET-driven cancers.	pyrimidine	31-41	ret proto-oncogene	Homo sapiens	195-198